You are here

tafamidis

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Fierce Pharma

clinical trials

Flag link:

Pfizer Lawsuit Seeks to Block Generic Copy of Heart Disease Blockbuster

Pfizer Lawsuit Seeks to Block Generic Copy of Heart Disease Blockbuster

BioSpace

Flag link:

Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

Fierce Pharma

Flag link:

Pfizer argues its case in federal court for helping seniors meet drug copays

Pfizer argues its case in federal court for helping seniors meet drug copays

Marketwatch

Flag link:

Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Fierce Pharma

Flag link:

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Fierce Pharma

ATTR amyloidosis

Flag link:

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Motley Fool

Akcea Therapeutics

Eidos Therapeutics

Flag link:

Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Forbes

Flag link:

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Flag link:

Pfizer prospects for tafamidis market

Pfizer prospects for tafamidis market

Biopharma Dive

transthyretin amyloid cardiomyopathy

Flag link:

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

CP Wire

transthyretin amyloid cardiomyopathy

Flag link:

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

transthyretin amyloid cardiomyopathy

Flag link:

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

Motley Fool

ATTR amyloidosis

Flag link:

Pfizer rare heart disease drug reduces risk of death by 30 percent in study

Pfizer rare heart disease drug reduces risk of death by 30 percent in study

Reuters

transthyretin amyloid cardiomyopathy

Flag link:

Pfizer's Next Blockbuster Drug Has Big Promise. We'll Find Out Monday How Much.

Pfizer's Next Blockbuster Drug Has Big Promise. We'll Find Out Monday How Much.

Bloomberg

transthyretin cardiomyopathy

clinical trials

Flag link:

Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition

Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition

CP Wire

transthyretin cardiomyopathy

Flag link:

Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition

transthyretin cardiomyopathy

Flag link:

Why Pfizer's Big Win Is Bad News for Alnylam and Ionis

Why Pfizer's Big Win Is Bad News for Alnylam and Ionis

Yahoo/Motley Fool

Ionis Pharmaceuticals

Flag link:

With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block

With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block

Fierce Pharma

Flag link:

Pfizer's rare heart disease drug succeeds in late-stage study

Pfizer's rare heart disease drug succeeds in late-stage study

Yahoo/Reuters

clinical trials

transthyretin cardiomyopathy

Ionis Pharmaceuticals

Flag link:

Pages